Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kingworld Medicines Group's basic earnings per share (Basic EPS) for the
six
months ended in Dec. 2025 was HK$0.03.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.02.
Kingworld Medicines Group's EPS without NRI for the
six
months ended in Dec. 2025 was HK$0.04.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was 0.03.
During the past 12 months, Kingworld Medicines Group's average EPS without NRIGrowth Rate was -63.20% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was -7.20% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 5.50% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was -5.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Kingworld Medicines Group's highest 3-Year average EPS without NRI Growth Rate was 23.80% per year. The lowest was -32.40% per year. And the median was -4.45% per year.
Kingworld Medicines Group (HKSE:01110) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Kingworld Medicines Group EPS (Basic) Related Terms
Kingworld Medicines Group EPS (Basic) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kingworld Medicines Group (HKSE:01110) has a EPS (Basic) of HK$0.02 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Kingworld Medicines Group and its competitors.
Is Kingworld Medicines Group's EPS (Basic) too high?
Kingworld Medicines Group's current EPS (Basic) is HK$0.02. Overall, Kingworld Medicines Group has a GF Score™ of 43/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kingworld Medicines Group's EPS (Basic) compare to competitors?
Kingworld Medicines Group's EPS (Basic) of HK$0.02 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Healthcare Providers & Services company?
A good EPS (Basic) depends on the Healthcare Providers & Services industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Kingworld Medicines Group and its competitors. Kingworld Medicines Group's current EPS (Basic) is HK$0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kingworld Medicines Group stock overvalued right now?
Based on GuruFocus' analysis, Kingworld Medicines Group (HKSE:01110) is currently considered Fairly Valued. The stock's GF Value™ is HK$0.50, compared to a current price of HK$0.48 — trading 5% below its estimated fair value. The current EPS (Basic) is HK$0.02. Kingworld Medicines Group's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Kingworld Medicines Group (HKSE:01110), the current EPS (Basic) is HK$0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kingworld Medicines Group (HKSE:01110) Overvalued in 2026?
Based on GuruFocus' analysis, Kingworld Medicines Group stock appears to be undervalued.
The current stock price of HK$0.48 is trading 5% below its estimated GF Value™ of HK$0.50.
GuruFocus considers Kingworld Medicines Group to be Fairly Valued.
Key valuation signals for HKSE:01110:
EPS (Basic): HK$0.02
GF Value™: HK$0.50 vs. price of HK$0.48 (5% below fair value)
No single metric tells the full story. See the HKSE:01110 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kingworld Medicines Group Ltd is engaged in the Distribution of pharmaceutical and healthcare products, such as branded imported pharmaceutical and healthcare products in Hong Kong and the PRC, and Manufacturing and sales of electrotherapeutic and physiotherapeutic devices and general medical examination devices carried out in the PRC. It derives the majority of its revenue from the Distribution sales of the pharmaceutical and healthcare products segment.
43GF Score
Get the complete analysis for HKSE:01110
EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01110 has been successfully added to your 
